Compare ALLO & HKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ALLO | HKD |
|---|---|---|
| Founded | 2017 | 2003 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 452.6M | 512.3M |
| IPO Year | 2018 | 2021 |
| Metric | ALLO | HKD |
|---|---|---|
| Price | $1.22 | $1.73 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 12 | 0 |
| Target Price | ★ $9.00 | N/A |
| AVG Volume (30 Days) | ★ 5.2M | 142.0K |
| Earning Date | 11-05-2026 | 02-26-2027 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 34.09 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $255.46 | N/A |
| P/E Ratio | ★ N/A | $14.10 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.04 | $1.26 |
| 52 Week High | $4.46 | $5.47 |
| Indicator | ALLO | HKD |
|---|---|---|
| Relative Strength Index (RSI) | 24.71 | 50.57 |
| Support Level | N/A | $1.63 |
| Resistance Level | $2.22 | $1.73 |
| Average True Range (ATR) | 0.08 | 0.06 |
| MACD | -0.00 | 0.00 |
| Stochastic Oscillator | 0.00 | 50.00 |
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
AMTD Digital Inc along with its subsidiaries, is mainly involved in the provision of digital solutions services. Its reportable segments are digital solutions services segment; hotel operations, hospitality and VIP services segment; media and entertainment services segment; and Strategic investments. The company generates maximum revenue from Digital solutions services segment, which provides its institutional and corporate clients with exclusive, paid access to enhance their investor communication, investor relations and corporate communication to potentially maximize their valuation, as well as providing digital solution services. Geographically, the company generates revenue from China, Hong Kong, Europe, Americas and Southeast Asia.